COVID Vaccines May Boost Cancer Survival Rates, Study Finds

According to a study published in the journal Nature last month, the COVID-19 mRNA vaccines developed by Moderna and Pfizer may provide an unexpected benefit for cancer patients. Researchers examined the clinical outcomes of over 1,000 late-stage melanoma and lung cancer patients who were undergoing immunotherapy treatment.

The study revealed that patients who received either the Moderna or Pfizer mRNA COVID-19 vaccine within 100 days of starting immunotherapy were more than twice as likely to survive for 3 years compared to those who did not get vaccinated. Remarkably, the vaccine's benefits were even more pronounced for patients whose tumors did not respond well to immunotherapy - these individuals were 5 times more likely to survive past 3 years if they had received the Pfizer or Moderna jab.

Experts say these findings suggest the mRNA vaccines may "prime" the immune system to better recognize and attack cancer cells when combined with immunotherapy. While more research is needed, this could represent a significant breakthrough in the fight against cancer. However, doctors caution that the COVID-19 vaccine should still be viewed primarily as a preventative measure against severe illness, not a cancer treatment.